These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 26796803)

  • 1. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
    Wan Y; Hui H; Wang X; Wu J; Sun S
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
    Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
    Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 4. Choice of Capecitabine or S1 in Combination with Oxaliplatin based on Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase Expression Status in Patients with Advanced Gastric Cancer.
    Xu R; He X; Wufuli R; Su Y; Ma L; Chen R; Han Z; Wang F; Liu J
    J Gastric Cancer; 2019 Dec; 19(4):408-416. PubMed ID: 31897343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
    Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J;
    Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
    Chen H; Xue L; Liu L; Li P
    J BUON; 2021; 26(3):917-923. PubMed ID: 34268954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of lobaplatin plus S-1 and the predictive value of circulating tumor cell in patients with advanced gastric cancer].
    Feng Q; Zhao JR; Zhang AX; Li SL
    Zhonghua Zhong Liu Za Zhi; 2018 Sep; 40(9):696-702. PubMed ID: 30293397
    [No Abstract]   [Full Text] [Related]  

  • 8. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
    Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.
    Dai X; Zhang X; Wang C; Jiang J; Wu C
    Oncotarget; 2017 May; 8(18):30495-30501. PubMed ID: 27911869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer.
    Shitara K; Kadowaki S; Nishina T; Sakai D; Yoshikawa R; Piao Y; Ozeki A; Inoue K; Gritli I; Muro K
    Gastric Cancer; 2018 Jan; 21(1):106-113. PubMed ID: 28667466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical study of tegafur-gimeracil-oteracil potassium capsule (s-1) and oxaliplatin combination chemotherapy in advanced colorectal cancer.
    Liu H; Wang Y; Li G; Song W; Wang R
    J Cancer Res Ther; 2015; 11(2):331-5. PubMed ID: 26148595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anlotinib combined with SOX regimen (S1 (tegafur, gimeracil and oteracil porassium capsules) + oxaliplatin) in treating stage IV gastric cancer: study protocol for a single-armed and single-centred clinical trial.
    Wang J; Wu DX; Meng L; Ji G
    BMJ Open; 2020 Jun; 10(6):e034685. PubMed ID: 32499264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tegafur + gimeracil + oteracil. Just another fluorouracil precursor.
    Prescrire Int; 2013 May; 22(138):122. PubMed ID: 23819172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.
    Nakamura Y; Yamanaka T; Chin K; Cho H; Katai H; Terashima M; Misawa K; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Bando H; Kawashima Y; Fukunaga T; Gotoh M; Ishibashi T; Shitara K
    Ann Surg Oncol; 2019 Feb; 26(2):465-472. PubMed ID: 30456678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
    Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
    Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 17. Tegafur gimeracil oter combined with oxaliplatin for advanced colorectal cancer.
    Yang ZH; Ren J; Yi LJ; Zheng JH; Wei H
    Eur Rev Med Pharmacol Sci; 2015 Sep; 19(18):3391-6. PubMed ID: 26439033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of SOX and CAPOX in patients with advanced gastric cancer after laparoscopic D2 gastrectomy: A randomized controlled trial.
    Liu X; Yan Y; Lu L; Liu Y; Ma J; Wang X; Wang D; Liu B; Liu Z; Zhou X; Cui H; Zhao Z; Li C; Liu J; Li W; Huang QX; Zhao Q; Liu T; Fu W
    Cancer Med; 2024 Jun; 13(11):e7326. PubMed ID: 38826114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).
    Boku N; Ryu MH; Kato K; Chung HC; Minashi K; Lee KW; Cho H; Kang WK; Komatsu Y; Tsuda M; Yamaguchi K; Hara H; Fumita S; Azuma M; Chen LT; Kang YK
    Ann Oncol; 2019 Feb; 30(2):250-258. PubMed ID: 30566590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetexal plus S-1 versus oxaliplatin plus S-1 for first-line treatment of patients with advanced gastric cancer: a retrospective study.
    Wang M; Wu M; Wang W; Wang Q; Wang Y
    Oncol Res Treat; 2014; 37(1-2):24-8. PubMed ID: 24613905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.